The impact of urological resection and reconstruction on patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

被引:4
|
作者
Tan, Grace Hwei Ching [1 ]
Shannon, Nicholas B. [2 ]
Chia, Claramae Shulyn [1 ]
Lee, Lui Shiong [3 ]
Soo, Khee Chee [1 ]
Teo, Melissa Ching Ching [1 ]
机构
[1] Natl Canc Ctr Singapore, Div Surg Oncol, Singapore, Singapore
[2] Duke NUS Med Sch, Singapore, Singapore
[3] Singapore Gen Hosp, Dept Urol, Singapore, Singapore
关键词
Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal carcinomatosis; Urological procedures; Urological reconstruction;
D O I
10.1016/j.ajur.2017.09.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are increasingly being used to treat peritoneal malignancies. Urological resections and reconstruction (URR) are occasionally performed during the surgery. We aim to evaluate the impact of these procedures on peri-operative outcomes of CRS and HIPEC patients. Methods: A retrospective review of a prospectively maintained database of all patients who underwent CRS-HIPEC from April 2001 to February 2016 was performed. Outcomes between patients who had surgery involving, and not involving URR were compared. Primary outcomes were the rate of major complications and the duration of stay in the intensive care unit (ICU) and hospital. Secondary outcomes were that of overall survival (OS) and prognostic factors that would indicate a need for URR. Results: A total of 214 CRS-HIPEC were performed, 21 of which involved a URR. Baseline clinical characteristics did not vary between the groups (URR vs. No URR). Urological resections comprised of 52% bladder resections, 24% ureteric resections, and 24% involving both bladder and ureteric resections. All bladder defects were closed primarily while ureteric reconstructions consisted of two end-to-end anastomoses, one ureto-uretostomy, five direct implantations into the bladder and three boari flaps. URR were more frequently required in patients with colorectal peritoneal disease (p = 0.029), but was not associated with previous pelvic surgery (76% vs. 54%, p = 0.065). Patients with URR did not suffer more serious complications (14% vs. 24%, p = 0.42). ICU (2.2 days vs. 1.4 days, p = 0.51) and hospital stays (18 days vs. 25 days, p = 0.094) were not significantly affected. Undergoing a URR did not affect OS (p = 0.99), but was associated with increased operation time (570 min vs. 490 min, p = 0.046). Conclusion: While concomitant URR were associated with an increase in operation time, there were no significant differences in postoperative complications or OS. Patients with colorectal peritoneal metastases are more likely to require a URR compared to other primary tumours, and needs to be considered during pre-operative planning. (C) 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:194 / 198
页数:5
相关论文
共 50 条
  • [1] Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy
    Cortes-Guiral, Delia
    Mohamed, Faheez
    Glehen, Olivier
    Passot, Guillaume
    [J]. EJSO, 2021, 47 (01): : 60 - 64
  • [2] Morbidity of the Abdominal Wall Resection and Reconstruction After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Nunez, Maria F.
    Sardi, Armando
    Nieroda, Carol
    Jimenez, William
    Sittig, Michelle
    MacDonald, Ryan
    Aydin, Nail
    Milovanov, Vladimir
    Gushchin, Vadim
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (05) : 1658 - 1663
  • [3] Morbidity of the Abdominal Wall Resection and Reconstruction After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Maria F. Nunez
    Armando Sardi
    Carol Nieroda
    William Jimenez
    Michelle Sittig
    Ryan MacDonald
    Nail Aydin
    Vladimir Milovanov
    Vadim Gushchin
    [J]. Annals of Surgical Oncology, 2015, 22 : 1658 - 1663
  • [4] Extended Survival in the Elderly Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Shankar, S.
    Sittig, M.
    Nieroda, C.
    MacDonald, R.
    Gushchin, V.
    Sardi, A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S103 - S103
  • [5] Outcome of Icelandic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) abroad
    Petursdottir, Astriour
    Gunnarsson, Orvar
    Valsdottir, Elsa B.
    [J]. LAEKNABLADID, 2020, 106 (7-8): : 344 - 348
  • [6] Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma
    Tan, Grace H. C.
    Cheung, Michelle
    Chanyaputhipong, Jendana
    Soo, Khee Chee
    Teo, Melissa C. C.
    [J]. ANNALS ACADEMY OF MEDICINE SINGAPORE, 2013, 42 (06) : 291 - 296
  • [7] An analysis of the morbidity associated with abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
    Parikh, Roneil
    Shah, Sanjana
    Dhurandhar, Vikrant
    Alzahrani, Nayef
    Fisher, Oliver M.
    Arrowaili, Arief
    Liauw, Winston
    Morris, David
    [J]. EJSO, 2019, 45 (03): : 394 - 399
  • [8] Predictors of Financial Toxicity Risk Among Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS–HIPEC)
    Yusuf Ciftci
    Shannon N. Radomski
    Fabian M. Johnston
    Jonathan B. Greer
    [J]. Annals of Surgical Oncology, 2024, 31 : 1980 - 1989
  • [9] Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Acs, Miklos
    Babucke, Maximilian
    Jusufi, Maximilian
    Kaposztas, Zsolt
    Slowik, Przemyslaw
    Hornung, Matthias
    Schlitt, Hans J.
    Panczel, Ivan
    Hevesi, Judit
    Herzberg, Jonas
    Strate, Tim
    Piso, Pompiliu
    [J]. INNOVATIVE SURGICAL SCIENCES, 2024, 9 (01): : 3 - 15
  • [10] The quest of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): searching for evidence
    Reymond, Marc A.
    [J]. PLEURA AND PERITONEUM, 2016, 1 (04) : 167 - 168